Medical Research
(H12)
IRS Verified
DX Registered
990 on File
ADENOID CYSTIC CARCINOMA RESEARCHFOUNDATION
Financial strength (30%)
95/100
Reliability (20%)
55/100
Effectiveness (25%)
78/100
Impact (25%)
No data yet
Register and add impact metrics to be rated above three stars
CharityAI™ Score
Not yet evaluated
Financial Overview — FY 2025
$1.2M
Total Revenue
$1.2M
Total Expenses
$2.2M
Net Assets
3
Employees
Revenue Sources
Expense Breakdown
Program Expense Ratio
83.5%
Fundraising Efficiency
N/A
Operating Reserve
21.31x
Liability-to-Asset
3.6%
Revenue Diversification
76.6%
Executive Compensation
$150K
Compared with Peers
FY 2025
Compared with 162 similar organizations
(United States, Medical Research, $1M–$10M in expenses), FY 2025.
This organization
Middle half of peers (P25–P75)
Peer median
| Ratio | This org | Peer median | Position (P10 → P90) | |
|---|---|---|---|---|
|
Program expense ratio
Program expenses / total expenses
· higher is better
|
83.5% | 83.4% |
P10P90
|
Above median |
|
Admin expense ratio
Management and general / total expenses
· lower is better
|
11.1% | 10.4% |
P10P90
|
Below median |
|
Fundraising expense ratio
Fundraising expenses / total expenses
· lower is better
|
5.4% | 2.9% |
P10P90
|
Below median |
|
Operating reserve
Months of expenses covered by net assets
· higher is better
|
21.3 mo | 13.3 mo |
P10P90
|
Above median |
|
Liabilities to assets
Total liabilities / total assets
· lower is better
|
3.6% | 13.2% |
P10P90
|
Top quarter |
|
Revenue concentration
Share of revenue from the largest source
· lower is better
|
76.6% | 90.6% |
P10P90
|
Above median |
|
Surplus margin
Surplus as a share of revenue
|
-5.4% | 4.6% |
P10P90
|
Financial History
| Year | Revenue | Expenses | Net Assets | Program % | Staff |
|---|---|---|---|---|---|
| 2025 | $1.2M | $1.2M | $2.2M | 83.5% | 3 |
| 2023 | $1.9M | $1.9M | $2.5M | 92.1% | 3 |
| 2022 | $1.4M | $1.6M | $2.5M | 93.2% | 2 |
| 2021 | $2.4M | $2.1M | N/A | — | 2 |
Donor Reviews
Write a ReviewNo reviews yet
Be the first to share your experience with this organization.